Night sky

How Psychedelics Work

Understanding what happens in the brain — and why integration is not optional

THE NEUROSCIENCE

What Actually Happens in Your Brain

Classical psychedelics — psilocybin, LSD, DMT, mescaline, and ayahuasca — produce their primary effects through agonist activity at the 5-HT2A serotonin receptor. This single mechanism produces a cascade of neurological changes that, taken together, explain both the profundity of the experience and the importance of what happens afterward.

The most significant change is what researchers at Imperial College London call increased neural entropy — a dramatic increase in the complexity and flexibility of brain activity. Ordinarily, the brain runs efficiently by following well-worn pathways — habitual patterns of thought, perception, and emotional response that have been reinforced over years. Under psychedelics, these constraints temporarily dissolve. Brain regions that do not normally communicate begin exchanging signals. New patterns of connection become possible. The mind becomes, for a period, genuinely and unusually plastic.

The Default Mode Network — Why the Ego Dissolves

The default mode network (DMN) is a set of brain structures responsible for self-referential thinking — the continuous internal narrative of 'I am this person, living this life, with these problems and these possibilities.' It is the neural substrate of the constructed self.

Psychedelics dramatically suppress DMN activity. The narrative self quiets. The habitual story about who you are and what is possible temporarily loosens its grip. This is experienced as ego dissolution — the sense that the boundary between self and world has become permeable or disappeared entirely.

This is not dangerous. For the vast majority of people in appropriate set and setting, it is profoundly therapeutic. The constructed self, for once, is not running the show.

Ordinary Brain Activity

Limited pathways

Under Psychedelics

Dense interconnectivity

Increased neural connectivity under psilocybin (adapted from Carhart-Harris et al., 2014)

The second major effect is neuroplasticity. Psychedelic compounds have been shown to rapidly upregulate BDNF — brain-derived neurotrophic factor — the protein responsible for growing new synaptic connections. This effect persists for weeks following a single administration (Ly et al., 2018). The brain is, for a period, genuinely more capable of forming new patterns than it ordinarily is.

This is the biological basis for the therapeutic potential of psychedelics. And it is the biological basis for why integration is not a nice-to-have addition to the experience. It is the mechanism through which the experience produces lasting change.

THE CHEMISTRY

Serotonin, MDMA, and Ketamine — Different Mechanisms

Not all psychedelic compounds work the same way:

Psilocybin and LSD work primarily through 5-HT2A agonism — the serotonin receptor pathway described above. The effect is a profound expansion of cognitive flexibility and a temporary dissolution of habitual mental patterns.

MDMA works differently — it produces a massive release of serotonin, dopamine, and norepinephrine simultaneously, creating states of profound empathy, emotional openness, and reduced fear response. This is why MDMA-assisted therapy has shown such remarkable results for PTSD — it allows traumatic memories to be reprocessed in a state of emotional safety that is otherwise very difficult to access.

Ketamine works through NMDA receptor antagonism — a fundamentally different mechanism. It produces rapid antidepressant effects, often within hours, and is currently the only psychedelic compound with regulatory approval for clinical use in most jurisdictions.

Ayahuasca contains DMT (a powerful 5-HT2A agonist) combined with MAOIs that allow it to be orally active. The experience is typically longer, more somatic, and more emotionally intense than psilocybin or LSD.

THE CRITICAL WINDOW

Why What Happens Afterward Matters More Than the Experience Itself

Here is the finding that changes everything about how we should think about psychedelic experiences:

The therapeutic effect is not produced by the pharmacological action of the substance alone. Research consistently demonstrates that the quality, depth, and structure of the psychological support provided after the experience is a primary determinant of outcomes (Bathje et al., 2022; Gorman et al., 2021).

The neuroplastic window — the period of elevated BDNF and increased synaptic flexibility — lasts for several weeks following a single experience. During this window, new neural pathways can be established with unusual ease. Old patterns can be genuinely revised rather than merely temporarily suppressed.

But this window is not self-directing. The brain in a neuroplastic state will consolidate whatever patterns are most consistently activated during that period. If the person returns to exactly the same environment, the same relationships, the same daily patterns — the brain consolidates those. The insight was real. The window was open. And the old architecture reasserted itself because nothing new was built in its place.

Integration is the deliberate, structured use of the neuroplastic window to build new architecture. It is not processing the experience. It is using the experience as the opening for a restructuring of the self — cognitively, physically, spiritually, and relationally.

Without it, even the most profound experience fades like a dream. With it, a single journey can reorganise the architecture of a life.

"The experience opens the door. Integration is the practice of learning to live in the light on the other side."

THE EVIDENCE

What Clinical Trials Have Demonstrated

Johns Hopkins

A single psilocybin session produced personality changes — specifically increases in openness — as large as those normally seen across decades of adult development.

MacLean et al., 2011

Johns Hopkins

The degree of mystical experience during a psilocybin session was the single strongest predictor of long-term positive outcomes across every condition studied.

Griffiths et al., 2006; 2016

Imperial College London

Psilocybin therapy produced rapid and sustained reductions in depression scores, with effects persisting at 6-month follow-up — compared to minimal change in the antidepressant comparison group.

Carhart-Harris et al., 2021

MAPS

MDMA-assisted therapy produced clinically significant reductions in PTSD symptoms in 67% of participants, compared to 32% in the placebo group.

Mitchell et al., 2021

NYU

Psilocybin produced immediate and sustained reductions in depression and anxiety in patients with life-threatening cancer diagnoses.

Ross et al., 2016

Meta-analysis

Active engagement with structured integration activities — journalling, meditation, somatic practices, therapy — was consistently associated with better outcomes than passive processing.

Bathje et al., 2022

Ready to prepare for your experience?